Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
PLoS Negl Trop Dis ; 9(4): e0003625, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25853654

RESUMO

Chagas disease, caused by Trypanosoma cruzi, is endemic in southern parts of the American continent. Herein, we have tested the protective efficacy of a DNA-prime/T. rangeli-boost (TcVac4) vaccine in a dog (Canis familiaris) model. Dogs were immunized with two-doses of DNA vaccine (pcDNA3.1 encoding TcG1, TcG2, and TcG4 antigens plus IL-12- and GM-CSF-encoding plasmids) followed by two doses of glutaraldehyde-inactivated T. rangeli epimastigotes (TrIE); and challenged with highly pathogenic T. cruzi (SylvioX10/4) isolate. Dogs given TrIE or empty pcDNA3.1 were used as controls. We monitored post-vaccination and post-challenge infection antibody response by an ELISA, parasitemia by blood analysis and xenodiagnosis, and heart function by electrocardiography. Post-mortem anatomic and pathologic evaluation of the heart was conducted. TcVac4 induced a strong IgG response (IgG2>IgG1) that was significantly expanded post-infection, and moved to a nearly balanced IgG2/IgG1 response in chronic phase. In comparison, dogs given TrIE or empty plasmid DNA only developed high IgG titers with IgG2 predominance in response to T. cruzi infection. Blood parasitemia, tissue parasite foci, parasite transmission to triatomines, electrocardiographic abnormalities were significantly lower in TcVac4-vaccinated dogs than was observed in dogs given TrIE or empty plasmid DNA only. Macroscopic and microscopic alterations, the hallmarks of chronic Chagas disease, were significantly decreased in the myocardium of TcVac4-vaccinated dogs. We conclude that TcVac4 induced immunity was beneficial in providing resistance to T. cruzi infection, evidenced by control of chronic pathology of the heart and preservation of cardiac function in dogs. Additionally, TcVac4 vaccination decreased the transmission of parasites from vaccinated/infected animals to triatomines.


Assuntos
Doença de Chagas/prevenção & controle , Vacinas Protozoárias/imunologia , Trypanosoma cruzi/imunologia , Vacinas de DNA/imunologia , Animais , Anticorpos Antiprotozoários/sangue , Doença de Chagas/imunologia , Cães , Ensaio de Imunoadsorção Enzimática , Imunoglobulina G/sangue , Interleucina-12/imunologia , Miocárdio/patologia , Parasitemia/imunologia , Plasmídeos/genética , Vacinas Protozoárias/administração & dosagem , Trypanosoma cruzi/genética , Vacinação , Vacinas de DNA/administração & dosagem
2.
Rev. colomb. cancerol ; 17(1): 18-24, ene.-mar. 2013. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-729550

RESUMO

Objetivos: Describir las características sociodemográficas y clínicas de un grupo de pacientes con cáncer de recto localmente avanzado, tratados con quimiorradioterapia neoadyuvante, y realizar un diagnóstico situacional del manejo. Métodos: Se realizó un estudio tipo series de casos, con la información clínica de 41 pacientes atendidos durante el 2010 en el instituto nacional de Cancerología. Resultados: la edad promedio de los pacientes observados fue de 61 años, con un el 61% de hombres; el estado funcional por Karnofsky fue igual o mayor que el 70%. El esquema neoadyuvante más utilizado fue 5 fluorouracilo y leucovorín en bolos, concomitante con radioterapia. De los pacientes, 30 completaron el tratamiento con buena tolerancia; 21 fueron llevados a cirugía, con preservación del esfínter en 10 de ellos; 18 lograron respuesta patológica; 14, parcial y 4, completa. Conclusión: los pacientes con cáncer de recto localmente avanzado que recibieron tratamiento neoadyuvante con quimiorradioterapia en el Instituto Nacional de Cancerología durante 2010 fueron, en su mayoría, hombres con buen estado funcional; el principal esquema de quimioterapia empleado fue 5 fluorouracilo y leucovorín en bolos, gracias a lo cual se logró resecabilidad del tumor, preservación del esfínter y respuesta patológica en aproximadamente la mitad de los pacientes.


Objectives: To describe the sociodemographic and clinical characteristics of a group of patients with locally advanced rectal cancer treated with neoadjuvant chemo-radiotherapy, and to make a situational diagnosis of the management. Methods: A case series study was conducted using the clinical information of 41 patients treated in the Instituto Nacional de Cancerología during the year 2010. Results: The mean age of the patients studied was 61 years, and 60% were male. The Karnofsky functional state was equal or greater than 70%. The neoadjuvant scheme most used was 5-fluorouracil and leucovorin in boluses, concomitant with radiotherapy. Of the 41 patients, 30 completed the treatment with good tolerance; 21 required surgery, with preservation of the sphincter in 10 of them; 18 achieved a pathological response; 14, partial and 4, complete. Conclusion: The patients with locally advanced rectal cancer who received neoadjuvant treatment with chemo-radiotherapy in the Instituto Nacional de Cancerología during the year 2010 were, mainly males with a good functional state. The principal chemotherapy scheme employed was 5-fluorouracil and leucovorin in boluses, due to which resectability of the tumour, preservation of the sphincter, and a pathological response in approximately half of the patients, was achieved.


Assuntos
Humanos , Neoplasias Retais , Terapia Neoadjuvante , Fluoruracila , Permissividade , Cirurgia Geral , Terapêutica , Estado , Métodos
3.
Rev. colomb. cancerol ; 16(2): 119-129, jun. 2012. tab
Artigo em Espanhol | LILACS | ID: lil-662991

RESUMO

El carcinoma córtico-adrenal es una entidad que se presenta raras veces; su evolución es agresiva, con una alta probabilidad de recaída y una supervivencia a 5 años que no supera el 60%. El único tratamiento curativo es la cirugía, siempre y cuando esta sea completa y a los pacientes se los diagnostique en estadios tempranos. Otras intervenciones que se pueden brindar son la radioterapia, la quimioterapia y el control de secreción hormonal en el contexto adyuvante o paliativo. En algunos casos (síndrome de Cushing) el bloqueo hormonal previo a la cirugía es imperativo. En esta revisión se describen la patogénesis, el diagnóstico, los factores pronósticos y el tratamiento del carcinoma córtico-adrenal, con el propósito de guiar el enfoque diagnóstico y el tratamiento.


Adrenal-cortical carcinoma is a rarely occurring entity; it evolves aggressively, has a high probability of relapse and survival at 5 years does not surpass 60%. Surgery provides the only curative treatment, but only when it is complete and carried out on patients with early-stage diagnosis. Additional treatments that may be used include radiotherapy, chemotherapy and control of hormonal secretion in an adjuvant or palliative context. In some cases (Cushing´s syndrome), it is imperative to provide hormonal block before surgery. The pathogenesis, diagnosis, prognostic factors and treatment of adrenal-cortical carcinoma are described in this review in order to sharpen the focus on diagnosis and treatment.


Assuntos
Humanos , Carcinoma Adrenocortical , Síndrome de Cushing , Metástase Neoplásica , Cirurgia Geral/métodos
4.
Lung Cancer ; 77(2): 469-72, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22534670

RESUMO

The use of erlotinib throughout pregnancy has not been previously reported. We present the case of a 40 year-old female patient with stage IV lung adenocarcinoma, mediastinal, bone and cerebral metastasis, a EGFR mutation and no smoking history, who had begun first line treatment with erlotinib 150 mg once daily. After two and a half months of treatment a fourteen-week pregnancy was documented, and after informing on fetal risks secondary to erlotinib use and maternal risks secondary to treatment withholding, she decided to continue with treatment under clinical surveillance by both the oncology and obstetrics clinics. At thirty-three weeks gestation a live born 1600 g female was born by caesarean section without evidence of congenital malformations. Imaging assessment after eight months of treatment showed complete bone and central nervous system response and partial lung and mediastinal response. The patient is currently undergoing the 11th month of treatment and is asymptomatic, the baby is 4 months old and is in good health.


Assuntos
Adenocarcinoma/tratamento farmacológico , Antineoplásicos/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Complicações Neoplásicas na Gravidez/tratamento farmacológico , Inibidores de Proteínas Quinases/uso terapêutico , Quinazolinas/uso terapêutico , Adenocarcinoma/diagnóstico , Adenocarcinoma/genética , Adulto , Sequência de Bases , Receptores ErbB/antagonistas & inibidores , Receptores ErbB/genética , Cloridrato de Erlotinib , Feminino , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/genética , Mutação , Metástase Neoplásica , Gravidez , Complicações Neoplásicas na Gravidez/diagnóstico , Resultado da Gravidez , Resultado do Tratamento
5.
Rev. colomb. cancerol ; 16(1): 49-58, mar. 2012. graf
Artigo em Espanhol | LILACS | ID: lil-662982

RESUMO

El hemangiosarcoma cutáneo es una enfermedad maligna rara de origen vascular, y corresponde a menos del 1% de todas las malignidades y al 2% de todos los sarcomas de tejidos blandos. Su presentación usual es en el rostro y en la región del cuero cabelludo; al momento de diagnosticarse ya es una enfermedad avanzada. Afecta a menudo al anciano del género masculino y de raza blanca. El tratamiento oncológico se basa en la resección quirúrgica, la radioterapia y la quimioterapia, dado el alto riesgo tanto de recaída local como de diseminación hematológica con intención paliativa. Las tasas de control locorregional a 5 años son, aproximadamente, del 40% al 50%, las tasas de supervivencia libre de metástasis a distancia a 5 años están en el rango del 20% al 40%, y las tasas de supervivencia a 5 años se encuentran entre el 10% y el 30%.


Cutaneous hemangiosarcoma is a rare malignant disease of vascular origin which accounts for less than 1% of all malignancies and 2% of all soft tissue sarcomas. It most frequently affects elderly white males, and is usually found on the face and scalp; at diagnosis it tends to be advanced. Oncologic treatment is based upon surgical resection, radiotherapy and chemotherapy due to the high risk of local relapse as well as to hematologic dissemination with palliative intention. Loco-regional control rates at 5 years range from 40% to 50%, metastasis-free survival rates at 5 years are from 20% to 40%, and survival rates at 5 years from 10% to 30%.


Assuntos
Humanos , Masculino , Feminino , Idoso , Biologia Molecular/classificação , Biologia Molecular/métodos , Hemangiossarcoma , Neoplasias Cutâneas , Tratamento Farmacológico/métodos , Radioterapia/métodos
6.
Transpl Int ; 20(10): 895-903, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17854447

RESUMO

The immunosuppressive effect of FTY720 is associated with the reversible sequestration of lymphocytes from the blood and the spleen into secondary lymphoid organs and reduced egress of mature thymocytes from the thymus. This work was designed to dissect the differential effect of FTY720 on CD4 and CD8 T cell-mediated mechanisms of skin graft rejection in the presence (euthymic) or absence (thymectomized) of thymic output. To that end, untreated and FTY720-treated euthymic (Euthy) and thymectomized (ATX) mice received skin allografts across a full, class II or class I major histocompatibility complex (MHC) mismatched (MM) barriers and graft survival was monitored. We demonstrate that a short course of FTY720 treatment significantly augments the survival of full, class I and class II MHC MM skin grafts compared to the nontreated controls. Interestingly, FTY720-treated Euthy recipients showed a significantly prolonged skin allograft survival compared to FTY720-treated ATX mice. These results together show that FTY720 impairs both CD4 and CD8 T cell-mediated mechanisms of rejection and, more importantly, the presence of the thymus is necessary for the ability of FTY720 to modulate skin allograft rejection across different histocompatibility MHC barriers.


Assuntos
Rejeição de Enxerto/prevenção & controle , Imunossupressores/farmacologia , Complexo Principal de Histocompatibilidade/imunologia , Propilenoglicóis/farmacologia , Transplante de Pele/imunologia , Esfingosina/análogos & derivados , Timo/imunologia , Animais , Modelos Animais de Doenças , Feminino , Cloridrato de Fingolimode , Citometria de Fluxo , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/patologia , Sobrevivência de Enxerto/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Esfingosina/farmacologia , Transplante Homólogo , Resultado do Tratamento
7.
Eur J Immunol ; 35(12): 3545-60, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16285013

RESUMO

Programmed death-1 (PD-1, CD279) is a molecule expressed on activated T, B and myeloid cells. The role of the interaction of PD-1 ligands (PD-L1 and PD-L2) with PD-1 receptor and the type of signals (costimulatory or inhibitory) that are delivered is a subject of intense debate. Our study has characterized two monoclonal antibodies (mAb) against murine PD-1, termed clone 1H10 and clone 4F10, that recognized different epitopes from that of anti-PD-1, clone J43. We showed that neither of them inhibited anti-CD3-mediated proliferation, but 1H10 mAb induced direct T cell proliferation in the absence of any other stimulus. Moreover, PD-1 engagement with 1H10 mAb costimulated anti-CD3-mediated proliferation and enhanced anti-CD3/CD28 proliferation on both CD4+ and CD8+ T cells in the low range of anti-CD3 concentrations. Anti-PD-1-mediated proliferation induced with 1H10 mAb was also observed in vivo on CD4+ and CD8+ T cells, when CFSE-labeled splenocytes were adoptively transferred to irradiated syngeneic and allogeneic recipients. Overall, our data indicate that PD-1 might not only deliver negative signals to T cells upon interaction through one of its ligands, PD-L1 as reported, but also could costimulate T cells, suggesting a dual potential functional activity of the extracellular domains of this receptor.


Assuntos
Adjuvantes Imunológicos/fisiologia , Anticorpos Monoclonais/fisiologia , Antígenos de Superfície/imunologia , Proteínas Reguladoras de Apoptose/imunologia , Antígenos CD28/fisiologia , Proliferação de Células , Ativação Linfocitária/imunologia , Linfócitos T/imunologia , Linfócitos T/metabolismo , Animais , Antígenos de Superfície/genética , Antígenos de Superfície/fisiologia , Proteínas Reguladoras de Apoptose/genética , Proteínas Reguladoras de Apoptose/fisiologia , Células CHO , Cricetinae , Cricetulus , Feminino , Hibridomas , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Receptor de Morte Celular Programada 1 , Ratos , Ratos Sprague-Dawley , Transdução de Sinais/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...